EV-301 update reinforces third-line enfortumab vedotin benefit in advanced UC | Jonathan Rosenberg

Jonathan Rosenberg takes us through the 2-year follow-up data from the EV-301 study comparing enfortumab vedotin with chemotherapy in previously treated patients with advanced urothelial cancer.
This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany
View more on Medicine Matters oncology: bit.ly/3zhWZn0